| Assessment Status | Awaiting full HTA submission from Applicant |
| HTA ID | 23073 |
| Drug | Tremelimumab |
| Brand | Imjudo® |
| Indication | Tremelimumab (Imjudo®) in combination with durvalumab (Imfinzi®) is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma. |
| Assessment Process | |
| Rapid review commissioned | 06/12/2023 |
| Rapid review completed | 11/01/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tremelimumab in combination with durvalumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 01/02/2024 |
| Pre-submission consultation with Applicant | 26/03/2024 |
